Bionik Laboratories (Bionik Laboratories) Debt-to-Equity : -1.47 (As of Mar. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Bionik Laboratories Debt-to-Equity?

Bionik Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.02 Mil. Bionik Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $2.39 Mil. Bionik Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $-1.64 Mil. Bionik Laboratories's debt to equity for the quarter that ended in Mar. 2023 was -1.47.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bionik Laboratories's Debt-to-Equity or its related term are showing as below:

BNKL's Debt-to-Equity is not ranked ^*
in the Healthcare Providers & Services industry.
Industry Median: 0.49
* Ranked among companies with meaningful Debt-to-Equity only.

Bionik Laboratories Debt-to-Equity Historical Data

The historical data trend for Bionik Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionik Laboratories Debt-to-Equity Chart

Bionik Laboratories Annual Data

Trend

Dec14

Dec15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.16

1.13

-1.47

Bionik Laboratories Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Equity	Get a 7-Day Free Trial															-	0.32	1.98	-3.57	-1.47

Competitive Comparison of Bionik Laboratories's Debt-to-Equity

For the Medical Care Facilities subindustry, Bionik Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bionik Laboratories's Debt-to-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Bionik Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bionik Laboratories's Debt-to-Equity falls into.

Bionik Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bionik Laboratories's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.022	+	2.39)	/	-1.641
	=	-1.47

Bionik Laboratories's Debt to Equity Ratio for the quarter that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.022	+	2.39)	/	-1.641
	=	-1.47

Bionik Laboratories (OTCPK:BNKL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bionik Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bionik Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionik Laboratories (Bionik Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Bionik Laboratories Corp (OTCPK:BNKL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Coolidge Hill Road, Watertown, MA, USA, 02472

Website

https://www.bioniklabs.com

Bionik Laboratories Corp is a healthcare company focused on improving the quality of life of millions of people with neurological or mobility impairments by combining artificial intelligence and innovative robotics technology to help individuals from hospital to home regain mobility, enhance autonomy, and regain self-esteem. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and more intuitive to deliver a greater recovery for patients with neurological or mobility impairments. Its products The InMotion ARM, and InMotion ARM/HAND are robotic therapies for the upper limbs.

Executives

Remi Gaston-dreyfus	director, 10 percent owner	46 RUE PIERRE CHARRON, PARIS I0 75008
Charles Matine	director	7 RUE GUSTAVE, FLAUBERT, PARIS I0 75017
Andre-jacques Auberton-herve	director, officer: Chairman	18 CHEMIN DE LA VIERGE NOIRE, LA TRONCHE I0 38700
Daniel Gonsalves	officer: Executive Vice President & CFO	80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Loren W. Wass	officer: See Remarks	34 HOG HILL ROAD, PEPPERELL MA 01463
Joseph R Martin	director
Audrey Thevenon	director	4500 WESTBROOK LANE, KENSINGTON MD 20895
Peter Gerald Malone	director
Russo Richard Paul Jr	officer: Chief Financial Officer	20 PLUNKETT WAY, TEWKSBURY MA 01876
Renaud Bertrand Maloberti	officer: Chief Commercial Officer	10 ACORN WAY, GEORGETOWN MA 01833
Timothy A. Mccarthy	officer: Chief Commercialization Office	C/O BIONIK, 483 BAY STREET, N105, TORONTO A6 M5G 2C9
Eric Michel Dusseux	director	1 RUE DU CAPOT, CALUIRE-ET-CUIRE I0 69300
Jules Marc Fried	officer: VP - U.S. Operations	C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Hermano Igo Krebs	officer: Chief Science Officer	C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Marc Mathieu	director	716 BROOKS AVENUE, VENICE CA 90291